Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of the ban on puberty blockers on the mental health of trans patients under the age of 18.

The emergency banning Order, restricting the sale or supply of puberty blockers, was introduced by the previous Government. The Order enables those who were already on a course of treatment with Gonadotrophin-Releasing Hormone Analogues, before 3 June 2024 from a UK based private or National Health Service provider, to continue to have them supplied. Those who were already on a course of treatment prescribed by an EEA or Switzerland registered prescriber can legally switch to a UK based prescriber to continue their treatment.

The expert Cass Review, which is one of the most comprehensive reviews of gender identity services for children and young people to date, states that the rationale for early puberty suppressing hormones to treat gender dysphoria is unclear and the effects on cognitive and psychosexual development are unknown. This Government will always act in the interests of patient safety, which is why the Secretary of State signalled his intention to renew the Order and consult on a permanent ban (subject to the outcome of the ongoing judicial review).

We are committed to implementing the recommendations of the Cass Review to ensure that young people presenting to the NHS with gender dysphoria are receiving appropriate and high-quality care. That is why NHS England and the National Institute of Health and Care Research, the research arm of the Department, are working together to commission a study into the potential benefits and harms of puberty suppressing hormones as a treatment option for children and young people with gender incongruence. The study team is now in place and are finalising their application for funding which will be assessed by an independent scientific review study ahead of the commencement of wider approvals, including ethics, and set up.

We will continue to monitor the impacts of the Order, including on mental health. Professor Louis Appleby, Chair of the National Suicide Prevention Strategy Advisory Group, has examined evidence for a large rise in suicides claimed by campaigners. His paper, which was published on 19 July 2024, concluded that the data do not support the claim that there has been a large rise in suicide in young gender dysphoria patients at the Tavistock clinic.

Some children and young people may be concerned by these changes. If they are already under the care of a Children and Young People’s mental health provider or the Child and Adolescent Mental Health Services, they can contact their team for advice. If they are not, their general practice team will be able to assess whether further referrals for mental health support are required. Patients can also be signposted to the advice on getting mental health support available on the NHS.UK website. Anyone in need of urgent support can contact NHS 111 and choose the mental health option, option two. Further details are available at the following link:

https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/

Professor Appleby’s paper is available at the following link:

https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust-independent-report